## Overview of FGF-23 and its utility in feline patients with CKD

Nov. 8th, 2022, PM 8:00- PM 9:00 (Taipei time)

The key learning objectives for this webinar are:

- To review how we can diagnose cats in IRIS stage 1 and 2 CKD
- To review what CKD-MBD is understand the role of FGF-23 in this condition
- To understand when and how to measure serum FGF-23 concentrations in cats with CKD
- To understand how we can interpret FGF-23 concentrations to inform our management of **CKD-MBD**



Dr Rebecca Geddes MA VetMB GPCert(FeIP) MVetMed PhD

**DipACVIM FHEA MRCVS** 

Dr Geddes is a RCVS Specialist in **Small Animal Internal Medicine** and ACVIM Board-Certified Small **Animal Internal Medicine** Specialist, as well as a lecturer in **Small Animal Internal Medicine** at the Royal Veterinary College.

**Dear Doctors.** 

Our understanding of feline chronic kidney disease (CKD) is advancing, and we now have more tools that ever before for diagnosing and monitoring this condition in the early stages. The mainstay of management for feline CKD is dietary intervention, which has been shown to slow disease progression and increase survival time. However, identifying when to start feeding a renal diet is not always straightforward due to the insensitivity of serum phosphate concentrations for assessing CKD-mineral and bone disturbances (CKD-MBD), what we used to refer to as renal secondary hyperparathyroidism. Now we have the ability to measure fibroblast growth factor-23 (FGF-23), a sensitive marker of early CKD-MBD, which allows us to detect cats in need of dietary phosphate restriction earlier and more accurately.

We sincerely welcome you to join our special webinar on FGF-23. Hope to see you there!



**Scan QRcode to Register** 

